Albane L.
- Country
- France
- Department
- Medical Oncology
Research Overview
- Adjuvant Pembrolizumab Versus Placebo in High-Risk Stage III Melanoma Post-Resection: A Randomized, Double-Blind Phase 3 EORTC Trial
- Phase III Randomized Trial of Intermittent vs. Continuous Androgen Deprivation Therapy with AR Pathway Inhibitors in Metastatic Hormone-Naïve Prostate Cancer
- Efficacy and Safety of RLY-2608 Plus Fulvestrant Versus Capivasertib Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer
Data & Insights
Has run more than one trial at 41 of 223 partner sites.
Specializations
Breast cancer and endocrine-based treatment
Clinical research includes hormone receptor-positive, HER2-negative, and HER2-positive breast cancer, with interest in early breast cancer, locally advanced disease, and metastatic breast cancer. The portfolio also extends to triple-negative breast cancer and biomarker-driven treatment selection.
- ER-positive / HER2-negative breast cancer
- HER2-positive breast cancer
- Triple-negative breast cancer
- PIK3CA-mutant advanced breast cancer
Work in this area reflects a strong therapeutic focus on endocrine therapy, anti-HER2 treatment, and biomarker-guided strategies in breast oncology.
Genitourinary cancers
Research activity covers prostate cancer, renal cell carcinoma, and urothelial carcinoma, including advanced, recurrent, and metastatic settings. The clinical landscape also includes muscle-invasive bladder cancer and high-risk disease requiring perioperative or maintenance treatment approaches.
- Metastatic castration-resistant prostate cancer
- Metastatic renal cell carcinoma
- Locally advanced urothelial carcinoma
- Muscle-invasive bladder cancer
The investigator is involved in androgen receptor pathway strategies, immune checkpoint inhibition, and targeted treatment combinations in genitourinary oncology.
Head and neck and upper aerodigestive tract malignancies
Clinical interests include head and neck squamous cell carcinoma, laryngeal and hypopharyngeal cancer, oral cavity and oropharyngeal cancer, as well as esophageal carcinoma. The research scope also reaches salivary gland and sinonasal tumors.
- Recurrent or metastatic head and neck squamous cell carcinoma
- Locally advanced head and neck cancer
- Esophageal cancer
- Salivary gland and sinonasal tumors
Therapeutic interest is centered on radiotherapy-based combinations, immunotherapy, and organ-preserving treatment approaches in upper aerodigestive tract cancers.
Lung, mesothelioma, and thoracic oncology
Research involvement includes non-small cell lung cancer, small cell lung cancer, ROS1-positive and other molecularly defined lung cancers, along with pleural mesothelioma. The clinical scope also covers advanced thoracic solid tumors with actionable alterations.
- Non-small cell lung cancer
- Extensive-stage small cell lung cancer
- ROS1-positive lung cancer
- Malignant pleural mesothelioma
Key therapeutic domains include targeted therapy, immunotherapy, and combination systemic treatment for advanced thoracic malignancies.
Gastrointestinal, ovarian, and rare solid tumors
Additional research spans colorectal cancer, gastric cancer, pancreatic adenocarcinoma, ovarian cancer, and selected sarcomas. The portfolio also includes neuroendocrine neoplasms, melanoma, and other rare advanced solid tumors.
- Colorectal cancer
- Gastric and gastroesophageal junction cancer
- Pancreatic ductal adenocarcinoma
- Ovarian and endometrial cancer
Therapeutic emphasis includes biomarker-selected treatment, immuno-oncology, and novel systemic approaches for difficult-to-treat solid tumors.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.